0001209191-21-028036.txt : 20210422
0001209191-21-028036.hdr.sgml : 20210422
20210422200340
ACCESSION NUMBER: 0001209191-21-028036
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210420
FILED AS OF DATE: 20210422
DATE AS OF CHANGE: 20210422
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Larson Tina Marriott
CENTRAL INDEX KEY: 0001856414
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 21846373
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-20
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856414
Larson Tina Marriott
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
President and COO
Common Stock
2021-04-20
4
J
0
52500
D
0
D
Class A Common Stock
2021-04-20
4
J
0
52500
A
52500
D
Stock Option (Right to Buy)
1.06
2021-04-20
4
C
0
712500
0.00
D
2028-07-22
Common Stock
712500
0
D
Stock Option (Right to Buy)
2.47
2021-04-20
4
C
0
150000
0.00
D
2030-12-30
Common Stock
150000
0
D
Stock Option (Right to Buy)
1.06
2021-04-20
4
C
0
712500
0.00
A
2028-07-22
Class A Common Stock
712500
712500
D
Stock Option (Right to Buy)
2.47
2021-04-20
4
C
0
150000
0.00
A
2030-12-30
Class A Common Stock
150000
150000
D
Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO.
Twenty-Five percent (25%) of the shares subject to the award shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
/s/ Jonathan Golightly, attorney-in-fact
2021-04-22
EX-24.4_980538
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Recursion Pharmaceuticals,
Inc. (the "Company"), hereby constitutes and appoints Louisa Daniels, Nathan
Hatfield and Jonathan Golightly, each, the undersigned's true and lawful
attorney-in-fact to:
(1) complete and execute Forms ID, 3, 4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his or her discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
(2) do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorney-in-fact shall deem
appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of April 6, 2021.
/s/ Tina Marriott Larson
_________________________________
Signature
Tina Marriott Larson
_________________________________
Print Name